Seagen Inc.

Vivian Trang

Matthew R Levengood

Peter Senter

Michael Feldhaus

Lori Westendorf

Shyra Gardai

Christopher Carosino

Che Leung-Law

Nicole Okeley

Noah Bindman

Divya Awasthi

Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.

CD47 antibodies and uses thereof for treating cancer

The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and/or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.

Selective drug release from internalized conjugates of biologically active compounds

The invention provides bivalent antibodies including two light and heavy chain pairs. The N-termini of one or both light and heavy chain pairs are linked via linkers comprising a protease cleavage site to coiled-coil forming peptides that associate to form a coiled coil reducing binding affinity of at least one light-heavy chain pair to a target.

Bivalent antibodies masked by coiled coils

Growing community of inventors

Bothell, WA, United States of America

Vivian Trang